Published in Blood Weekly, May 13th, 2004
According to recent research from Seattle, the "clinical significance of early air flow decline after myeloablative allogeneic hematopoietic SCT is uncertain.
To rectify this, J.W. Chien and colleagues at the Fred Hutchinson "performed a retrospective cohort analysis to determine if airflow decline by day 100 is associated with later development of transplant-related airflow obstruction (AFO) and increased mortality risk.
"Overall, 750 (40%) patients had airflow decline by day 100," they wrote in the journal Bone Marrow...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.